Skip to main content

Clinical Trials Using Atezolizumab

Review the clinical trials studying atezolizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 100

Valemetostat and Atezolizumab for the Treatment of Extensive-Stage Small Cell Lung Cancer
Status: Active
Location: 2 locations
Atezolizumab with Stereotactic Body Radiation Therapy and Surgery for the Treatment of Patients with Osteosarcoma with Pulmonary Metastasis
Status: Active
Location: 2 locations
Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA
Status: Active
Location: MedStar Georgetown University Hospital, Washington, District of Columbia
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Vismodegib and Atezolizumab for the Treatment of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical, Vaginal, or Vulvar Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Atezolizumab and Tiragolumab for the Treatment of Patients with Refractory Locally Advanced, Metastatic or Recurrent Cancer of Unknown Primary
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non-squamous Non-small Cell Lung Cancer and Untreated Brain Metastases
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults with Recurrent or Metastatic Osteosarcoma, TACOS Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab with Y90 Radioembolization for the Preparation for Liver Transplantation for Patients with Hepatocellular Carcinoma
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Lamivudine in Combination with Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Tiragolumab and Atezolizumab for the Treatment Newly Diagnosed PD-L1 Positive Resectable Stage III-IV Oral Cavity Squamous Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined with Immune Checkpoint Inhibition after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Atezolizumab, Doxorubicin, and Radiation Therapy before Surgery for the Treatment of Stage III Localized, Resectable Soft Tissue Sarcoma of the Trunk and Extremities, SATURN-STS Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Atezolizumab and Pirfenidone for the Treatment of Non-small Cell Lung Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Tocilizumab and Atezolizumab for the Treatment of Patients with Refractory, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania